Arch Oncology Appoints Laurence Blumberg, M.D. President and CEO

BRISBANE, CA and ST. LOUIS, MO, April 7, 2021 – Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced the appointment of Laurence Blumberg, M.D. as President and Chief Executive Officer and Board Member. Dr. Blumberg has over thirty years of biotechnology industry experience as an executive, founder, analyst, and board member.

“On behalf of the Board, I welcome Laur to Arch Oncology as he brings extensive industry experience to lead the Company’s plans for AO-176, a novel anti-CD47 therapy for patients with cancer,” said John McKearn, Ph.D., Managing Director, RiverVest Venture Partners and Chairman of the Board of Arch Oncology. “AO-176 has a differentiated and potentially best-in-class profile among anti-CD47 biologic therapies and we look forward to Laur leading the team’s progress as they work to deliver this novel therapy to patients.”

Dr. Blumberg, added, “I am excited to join this team to build on the important work underway. With the ongoing clinical trials for AO-176 in patients with solid tumors and hematologic malignancies, I look forward to reaching multiple upcoming milestones, including the first reported clinical data mid-year 2021. This is an exciting moment in our Company’s evolution as we continue our mission on behalf of patients with cancer who need better therapeutic options.”

He received a B.A. from Brandeis University, an M.D. from Temple University School of Medicine, and an Executive MBA from Columbia University School of Business. He completed an Internship in Surgery at Abington Memorial Hospital and was an Otolaryngology resident at Geisinger Medical Center prior to his biotechnology career.

About Arch Oncology

Arch Oncology, Inc. is a privately-held, clinical-stage immuno-oncology company focused on the discovery and development of potential best-in-class antibody therapies for the treatment of patients with solid tumors and hematologic malignancies. The Company’s next-generation anti-CD47 antibodies are highly differentiated, with the potential to improve upon the safety and efficacy profile relative to other agents in this class. Arch Oncology’s lead product candidate AO-176 is in Phase 1/2 clinical trials for the treatment of patients with select solid tumors and with hematologic malignancies, both as monotherapy and in combination with standard therapies. In addition, the Company is advancing a pipeline of antibody programs for the treatment of cancer. For more information please visit

Media Contact:
Amy Figueroa, CFA
For Arch Oncology